Minoryx Therapeutics BE
La probabilité de faillite calculée de Minoryx Therapeutics BE sur 12 mois est de 0,7% (faible). L'entreprise est active depuis 2018 et le Moniteur belge ne contient aucun signal d'insolvabilité ou d'avertissement. Aucun chiffre de comptes annuels traité n'est disponible ; cette conclusion repose uniquement sur les données du registre et du Moniteur belge.
| Active | 7 ans |
| Direction | 2 |
| Sites | 1 |
| Publications | 3 |
Estimation statistique fondée sur des sources publiques, pas un conseil de crédit ni une constatation. Comment calculons-nous cela ?
| Exercice | Type | Dépôt | Référence |
|---|---|---|---|
| 31-12-2024 | volledig | 22-06-2025 | 2025-00161280 |
| 31-12-2023 | volledig | 23-06-2024 | 2024-00151367 |
| 31-12-2022 | volledig | 27-06-2023 | 2023-00162471 |
| 31-12-2021 | volledig | 13-07-2022 | 2022-20178918 |
| 31-12-2020 | micro | 22-07-2021 | 2021-38000444 |
| 31-12-2019 | micro | 12-07-2020 | 2020-28200272 |
| 31-12-2018 | volledig | 28-06-2019 | 2019-28700577 |
-
MARTINELL PEDEMONTE MarcAdministrateurActe Moniteur 23455066 (12-12-2023)Actif12-12-2023 → auj.
-
Minoryx Therapeutics SLPersonne moraleAdministrateur· repr. perm.: Minoryx Therapeutics SLActe Moniteur 23455066 (12-12-2023)Actif12-12-2023 → auj.
| NACE primaire | Recherche-développement en autres sciences physiques et naturelles(72109) |
| Forme juridique | SA(014) |
| Date de constitution | 28-11-2018 |
| Status | Actif |
| Code postal | 6041 |
Parcelles liées à cette entreprise via ses adresses BCE (siège, unités d'établissement, succursales), croisées avec le plan parcellaire cadastral. Ceci montre où l'entreprise est active, pas un registre de propriété.
| Parcelle (capakey) | Région | Superficie | Bâtiments | Hauteur / ét. |
|---|---|---|---|---|
| 52028B0315/18E000 | Wallonie | 2 954 m² | 1 · 670 m² | 10,0 m · 2 ét. |
Une seule chronologie de tout ce qui est arrivé à cette entreprise, publications, événements d'insolvabilité et de cycle de vie, changements administratifs et comptes annuels déposés.
Nous connaissons 9 actes du Moniteur belge pour cette entreprise. Aucun n'a encore été lu : ce qui s'y trouve n'a ici été ni constaté ni réfuté.
12-12-2023 Augmentation de capital de 3.000.000 € à 6.721.710 €
- €3.721.710 → €6.721.710
- Inbreng in geld · Apport en numéraire
- 2 kapitaalbewegingen in deze akte
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 6721710.0,
"delta_eur": 3000000.0,
"before_eur": 3721710.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 3000000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 5285156.0,
"delta_eur": -1436554.0,
"before_eur": 6721710.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "kapitalisering_reserves",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "Gewone Aandelen",
"n_new_shares": 5000000,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTAIRES",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2023-12-12",
"filing_date": "2023-12-07",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2023-11-27",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0713.984.534",
"name_full": "Minoryx Therapeutics BE",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal",
"procuration",
"texte coordonn\u00E9 des statuts"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 5000000,
"class_name": "Gewone Aandelen",
"capital_share_eur": 5285156.0,
"voting_rights_per_share": 1.0
}
]
}23-03-2023 Transfert du siège social vers Gosselies
- Avenue Jean Mermoz 32/6, 6041 Gosselies
Détails techniques
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "Avenue Jean Mermoz 32/6, 6041 Gosselies",
"city": "Gosselies",
"region": "waals_gewest",
"street": "Avenue Jean Mermoz",
"country": "BE",
"postcode": "6041",
"box_number": null,
"street_number": "32/6",
"locality_suffix": null
},
"old_address": null,
"effective_date": null,
"evidence_quote": "1. transf\u00E9rer le si\u00E8ge de la Soci\u00E9t\u00E9 \u00E0 Avenue Jean Mermoz 32/6, 6041 Gosselies.",
"region_changed": false,
"is_statute_change": true,
"nationality_change": false,
"old_address_source": "inferred",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": null,
"statutaire_vs_werkelijke": null,
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": null,
"filing_date": "2023-03-13",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "conseil_d_administration",
"date": "2023-03-02",
"unanimous": true
},
"subject_company": {
"kbo": "0713.984.534",
"name_full": "Minoryx Therapeutics BE",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Anthea Debou",
"org_rep_person_name": null,
"person_role_at_subject": "Mandataire"
},
"co_filed_documents": [
"Copie \u00E0 publier aux annexes au Moniteur belge"
]
}09-12-2022 Réduction de capital de 3.278.290 € à 3.721.710 €
- €7.000.000 → €3.721.710
- 2 kapitaalbewegingen in deze akte
Détails techniques
{
"events": [
{
"kind": "capital_increase",
"after_eur": 7000000.0,
"delta_eur": 2000000.0,
"before_eur": 5000000.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 2000000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 3721710.0,
"delta_eur": -3278290.0,
"before_eur": 7000000.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "kapitalisering_reserves",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
}
],
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": "BERQUIN NOTAIRES",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2022-12-09",
"filing_date": "2022-12-07",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2022-12-05",
"unanimous": null,
"under_authorized_capital": true,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0713.984.534",
"name_full": "Minoryx Therapeutics BE",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal",
"procuration",
"texte coordonn\u00E9 des statuts"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 5000000,
"class_name": "actions",
"capital_share_eur": 3721710.0,
"voting_rights_per_share": 1.0
}
]
}| Dénomination légaleFR | Minoryx Therapeutics BE |